Vigil™

Phase 3Biologic

GGradalis, Inc.

Vigil™ is one of 164 biologic programs targeting Colorectal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

163

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Ovarian CancerActive, not recruiting

NarcolepsyActive, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

NarcolepsyPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Vigil™

GGradalis, Inc.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

REGN2810

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Ovarian Cancer

NCT02346747

Clinical

Trials by Indication[1]

Ewing's Sarcoma2 trials

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated·GGradalis, Inc.·Phase 3·NCT03495921·32 enrolled

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed·GGradalis, Inc.·Phase 2·NCT02511132·22 enrolled

Ovarian Cancer2 trials

A Trial of Vigil for Participants With Ovarian Cancer

Active, not recruiting·GGradalis, Inc.·Phase 2·NCT02346747·92 enrolled

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Completed·GGradalis, Inc.·Phase 2·NCT01309230·39 enrolled

Melanoma2 trials

Phase II FANG™ in Advanced Melanoma

Terminated·GGradalis, Inc.·Phase 2·NCT01453361·18 enrolled

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Completed·GGradalis, Inc.·Phase 1·NCT02574533·2 enrolled

Advanced Cancer1 trial

Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Completed·GGradalis, Inc.·Phase 1·NCT01061840·100 enrolled

Pilot Study1 trial

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Completed·MMary Crowley Medical Research Center·Phase 2·NCT02725489·13 enrolled

8 more indications

Narcolepsy1 trial

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

Completed·BBioprojet·Phase 3·NCT01638403·180 enrolled

Non-Small Cell Lung Cancer1 trial

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Withdrawn·GGradalis, Inc.·Phase 2·NCT02639234

MACE1 trial

Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05855187·30 enrolled

Colorectal Carcinoma1 trial

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Terminated·GGradalis, Inc.·Phase 2·NCT01505166·3 enrolled

Carboplatin1 trial

Salvage Ovarian FANG™ Vaccine + Carboplatinum

Completed·GGradalis, Inc.·Phase 2·NCT01867086·1 enrolled

Bevacizumab1 trial

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Completed·GGradalis, Inc.·Phase 2·NCT01551745·5 enrolled

Solid Tumors1 trial

Expanded Access of Vigil in Solid Tumors

Temporarily not available·GGradalis, Inc.··NCT03842865

Advanced1 trial

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Completed·GGradalis, Inc.·Phase 2·NCT03073525·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Vigil™. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vigil™ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vigil™. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gradalis, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GGradalis, Inc.

Vigil™

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ewing's Sarcoma2 trials

Ovarian Cancer2 trials

Melanoma2 trials

Advanced Cancer1 trial

Pilot Study1 trial

Narcolepsy1 trial

Non-Small Cell Lung Cancer1 trial

MACE1 trial

Colorectal Carcinoma1 trial

Carboplatin1 trial

Bevacizumab1 trial

Solid Tumors1 trial

Advanced1 trial

References

Drug Info

Quick Facts

Related News